newsfilter
← Latest News
GlobeNewswire·

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today